Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

Revenue projections:

Revenue projections for SANOFI
Revenue projections for SANOFI

SANOFI is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 1.849000
forwardPE 27.931936
debtToEquity 2.672000
earningsGrowth -0.326000
revenueGrowth -0.123000
grossMargins 0.508400
operatingMargins 0.211170
trailingEps 157.520000
forwardEps 203.770000

Sanofi India Limited's current ratio, being 1.849, means the company is well-positioned to meet its short-term debt obligations. This reflects Sanofi India Limited's strong liquidity, as its cash reserves and current assets provide more than enough coverage for its immediate liabilities.
SANOFI's Forward PE ratio is favorable, meaning the stock price aligns well with earnings and isn't overvalued. This allows room for growth, making it an attractive investment for those seeking potential upside while ensuring the stock is not overpriced.
SANOFI's low earnings and revenue growth suggest shrinking profits are likely. This could reflect broader financial struggles, signaling that the company might face difficulties in sustaining its profitability.
SANOFI's positive gross and operating margins suggest that the company is operating profitably. These strong margins indicate effective cost management and revenue generation, contributing to a solid financial foundation.
SANOFI's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.

Price projections:

Price projections for SANOFI
Price projections for SANOFI

Sanofi India Limited's price projections have gradually decreased, reflecting a less optimistic view of the company's future performance. Analysts are adjusting their expectations, suggesting potential concerns about Sanofi India Limited's ability to meet previous growth targets.

Recommendation changes over time:

Recommendations trend for SANOFI
Recommendations trend for SANOFI


A recent buy bias from analysts toward SANOFI indicates strong confidence in the stock's future performance. This could encourage investors to park their money in SANOFI, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.